Analyst Ratings For NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)
Today, NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO) stock received an upgrade by Morgan Stanley from Equal Weight to Overweight.
Some recent analyst ratings include
- 4/16/2018-Morgan Stanley Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.
- 4/16/2018-William Blair Reiterated Rating of Buy.
- 3/5/2018-Citigroup Reiterated Rating of Buy .
- 3/2/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 3/1/2018-Cann Reiterated Rating of Buy.
- 2/22/2018-CIBC initiated coverage with a Outperform rating.
- 2/22/2018-Oppenheimer initiated coverage with a Outperform rating.
- On 3/14/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.54 per share and the total transaction amounting to $1,973,100.00.
- On 3/14/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $131.41 per share and the total transaction amounting to $405,005.62.
- On 3/13/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $131.33 per share and the total transaction amounting to $223,261.00.
- On 2/13/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $96.57 per share and the total transaction amounting to $1,448,550.00.
- On 2/13/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $96.34 per share and the total transaction amounting to $296,919.88.
- On 2/12/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $93.24 per share and the total transaction amounting to $158,508.00.
- On 1/22/2018 Avi Z Naider, Director, sold 15,000 with an average share price of $100.00 per share and the total transaction amounting to $1,500,000.00.
Recent Trading Activity for NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)
Shares of NASDAQ:LOXO – Loxo Oncology closed the previous trading session at 127.32 up +4.33 3.52% with 176298 shares trading hands.